Abstract: The present invention encompasses compounds of Formula 1: as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.
Type:
Grant
Filed:
January 15, 2003
Date of Patent:
January 20, 2009
Assignee:
Merck & Co., Inc.
Inventors:
Robert L. Bugianesi, George A. Doherty, Amy Gentry, Jeffrey J. Hale, Christopher L. Lynch, Sander G. Mills, William E. Neway, III
Abstract: The present invention is directed to certain phenyl pyrrolidine ether compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, depression, and anxiety.
Type:
Grant
Filed:
September 24, 2004
Date of Patent:
December 23, 2008
Assignee:
Merck & Co., Inc.
Inventors:
Robert J. DeVita, Peter Lin, Sander G. Mills, Jonathan R. Young
Abstract: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Pagets disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.
Type:
Grant
Filed:
September 15, 2003
Date of Patent:
October 7, 2008
Assignee:
Merck & Co., Inc.
Inventors:
Dann LeRoy Parker, Robert R. Wilkening, Dongfang Meng, Ronald W. Ratcliffe